XENE PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

XENE ▼ -0.43% at T+20d

SHORT call ✓ call won +0.43% · α vs SPY +10.21% · entry $57.65 → $57.40

Next anchor: T+60d in 6w

Currently $54.68 · +5.15% from $57.65 entry (call sign-flipped)

Entry anchored
Apr 7, 05:11 AM ET
via Databento tick

T+1d

-0.19%

call +0.19% · α +2.73%

$57.54

settled 6w ago

T+5d

+2.95%

call -2.95% · α +2.38%

$59.35

settled 5w ago

T+20d

-0.43%

call +0.43% · α +10.21%

$57.40

settled 15d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS of -$1.31 versus consensus of -$1.20, a 9.4% negative surprise. The company highlighted upcoming Phase 3 X-TOLE2 data presentations at AAN 2026, including long-term efficacy and safety data for azetukalner in focal onset seizures, but provided no revenue or guidance updates.

Actionable Insight

The EPS miss and lack of revenue/guidance updates are negative signals; traders should monitor the AAN presentations for clinical data that could support future commercial potential of azetukalner, but near-term sentiment may remain pressured.

Key Facts

Reported Q4 2025 EPS of -$1.31, missing consensus of -$1.20 by 9.4%
Reported revenue of $1.0M, in line with consensus
No revenue or earnings guidance was provided
Announced five abstracts at AAN 2026, including a Late-breaking Science oral presentation of Phase 3 X-TOLE2 topline results for azetukalner in focal onset seizures
Presented long-term 48-month data from X-TOLE open-label extension and real-world burden of titration in epilepsy

Financial Impact

EPS miss of 9.4% below expectations, no revenue growth or guidance provided

epsrevenue

Risk Factors

Clinical data from X-TOLE2 may not meet efficacy or safety expectations
Delayed or failed regulatory approval for azetukalner
Dilution risk from future capital raises given negative EPS and limited revenue

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3269108

8 reports for XENE

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +6.59%Apr 15, 2026

Filters

Reports for XENE — sortable, filterable
	Type				Now
May 7, 2026 13d ago	Press Release MIXED ★ 6/10	$56.44 $56.00	▼ −0.78%	▼ −2.24%	$54.68 (−3.12%)
Apr 22, 2026 28d ago	DEFA14A NEUTRAL ★ 2/10	$55.41 $55.75	▲ +0.61%	▼ −0.86%	$54.68 (−1.32%)
Apr 19, 2026 4w ago	Press Release BULLISH ★ 8/10	$57.09 $54.26	▼ −4.96%	▼ −5.87%	$54.68 (−4.22%)
Apr 15, 2026 5w ago	Press Release BEARISH ★ 5/10	$58.88 $56.65	▲ +3.79%	▲ +5.43%	$54.68 (+7.13%)
Apr 13, 2026 5w ago	8-K NEUTRAL ★ 3/10	$59.35 $56.40	▼ −4.97%	▼ −6.36%	$54.68 (−7.87%)
Apr 7, 2026 6w ago	Press Release BEARISH ★ 5/10	$57.65 $59.35	▼ −2.95%	▲ +2.38%	$54.68 (+5.15%)
Mar 13, 2026 9w ago	Insider Cluster BEARISH ★ 6/10	$55.23 $54.94	▲ +0.53%	▼ −1.59%	$54.68 (+1.00%)
Mar 12, 2026 9w ago	Press Release NEUTRAL ★ 5/10	$55.23 $54.94	▼ −0.53%	▲ +1.59%	$54.68 (−1.00%)

US Market Status

Market Closed — Opens Thu (< 1m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access